MSC Therapy for Alzheimer’s Disease: Clinical Trial Data on Laromestrocel and Biomarker Outcomes

Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer's patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.

Read more...

MSC Therapy for Systemic Sclerosis: iPSC-Derived Stem Cells, Clinical Trials, and the Vasculopathy-Fibrosis Mechanism

A comprehensive 2026 review of mesenchymal stem cell therapy for systemic sclerosis (scleroderma), covering iPSC-derived MSCs, refrigerated cell delivery, blood vessel organoid models, and the MANUS clinical trial for digital ulcers.

Read more...
Top